

## RATIONALE

Adeno-pituitary tumour represents a complex disease, with a wide spectrum of clinical manifestations, according to the ability of secreting different hormones or pro-hormones and of invading the neighbouring anatomical structures, such as the same pituitary gland, the optical chiasm, the cavernous sinus, the bone, the third ventricle and the ventricular system.

In the most recent years, a better definition of these neoplasia was researched in order to identify biomarkers able to predict the natural history of adeno-pituitary tumour and their responsiveness to the different treatments.

Until now, the classifications of the neoplasms arising from adeno-hypophysial cells have been misleading because of their poor reproducibility and their weak ability in predicting the aggressiveness, the prognosis, and the outcome of these neoplasia. The 2004 WHO classification distinguished pituitary adenoma in typical and atypical ones according to the detection of mitoses and according to the expression of Ki-67 or p53. The 2004 WHO classification however failed in identifying pituitary tumours refractory to medical, surgical or radiation therapies or able to regrowth or to metastasize. Similarly, the new 2017 WHO classification lacks in defining the prognosis of pituitary neoplasia. Invasive, recurrent and proliferative pituitary neoplasia cause significant morbidity, in particular in cases of persistence hormonal hyper-secretion. Both long term hormonal hyper-secretion and hypopituitarism, in absence of an adequate hormonal replacement therapy, are associated to increased morbidity and mortality for their systemic complications, in particular bone fragility, that represent an emerging and irreversible complication requiring a prompt and personalities treatment.

Therefore, recently, adeno-pituitary tumours were included in neuroendocrine tumours (NETs). This new terminology of pituitary neuroendocrine tumor (PitNET) may reflect better the potential for aggressiveness and malignant behaviour and of these neoplasia. Anyway a consensus on PitNETs was not jet reached.

On this basis, in the recent years, a wide number of research investigated the genetic, molecular and biological features of PitNETs, in order to predict the clinical behaviour of these neoplasia and to personalize the treatments in not-secreting and secreting tumors as prolactinoma, acromegaly, Cushing disease. The current event has the aim of updating participants on the latest biological, genetic and clinical acquisitions on PitNET and on their impact in the management of PitNET affected patients according to the new knowledge, that requires a close clinical collaboration between pathologists, neurosurgeries and endocrinologists.

The meeting is part of the teaching activities of the Master Degree in Diagnosis and Treatment of pituitary disease (2024) - Faculty of Medicine, Università' Cattolica del Sacro Cuore, Rome.

### PRESIDENTE DEL CONGRESSO

**Prof. Alfredo Pontecorvi**

Direttore del Master Universitario di II Livello in diagnosi e terapia delle patologie ipotalamo-ipofisarie  
Università Cattolica del Sacro Cuore

### RESPONSABILI SCIENTIFICI

**Prof.ssa Laura De Marinis**

Coordinatore Scientifico del Master Universitario di II Livello in diagnosi e terapia delle patologie ipotalamo-ipofisarie - Università Cattolica del Sacro Cuore - Roma

**Dott. Antonio Bianchi**

Dirigente medico I livello U.O.S. di Patologie Ipotalamo-ipofisarie - Fondazione Policlinico Universitario A. Gemelli - IRCCS Roma

### SEDE

**Hotel Donna Camilla Savelli**  
Via Garibaldi 27, 00153 Roma RM

### PROVIDER E SEGRETERIA ORGANIZZATIVA



**DOTCOM S.r.l. Unipersonale**

Provider Standard accreditato presso la Commissione Nazionale ECM - ID 680

Via Flaminia, 54 | 00196 Roma

Tel. 06 4061370 | Fax 06 3242600 | E-Mail: info@dotcomeventi.com | [www.dotcomeventi.com](http://www.dotcomeventi.com)

### ECM 680 - 429184

L'evento è accreditato per n° 100 partecipanti per le seguenti figure professionali:

- **Medico - Chirurgo:** Anatomia Patologica, Chirurgia Generale, Endocrinologia, Gastroenterologia, Genetica Medica, Malattie Metaboliche e Diabetologia, Medicina Interna, Medicina Nucleare, Neurochirurgia, Neuroradiologia, Oftalmologia, Otorinolaringoiatria, Patologia Clinica (Laboratorio di Analisi Chimico- Cliniche e Microbiologia), Radiodiagnostica, Radioterapia.
- **Infermiere**

**Assegnati n. 10 crediti formativi ECM**

### OBIETTIVO FORMATIVO

Documentazione clinica. Percorsi clinico-assistenziali diagnostici e riabilitativi, profili di assistenza - profili di cura

### PRE-ISCRIZIONE

La pre-iscrizione potrà essere effettuata online collegandosi al sito [www.dotcomeventi.com](http://www.dotcomeventi.com) nella sezione "EVENTI & CONGRESSI IN CORSO". L'accesso in aula è riservato ai primi 100 partecipanti. Si ricorda che l'attestazione dei crediti formativi ECM è subordinata alla partecipazione del 90% della durata dei lavori, alla compilazione della scheda di valutazione dell'evento e al superamento della prova di apprendimento (questionario, almeno 75% risposte esatte).

Con la sponsorizzazione non condizionante di



Con il patrocinio di

**Gemelli**

Fondazione Policlinico Universitario Agostino Gemelli IRCCS  
Università Cattolica del Sacro Cuore



Patrocinio richiesto

**sie** Società Italiana  
Endocrinologia

[www.ipofisicrescitadintorni.it](http://www.ipofisicrescitadintorni.it)

11<sup>th</sup> ANNUAL MEETING ON PITUITARY TUMORS

EVENTO  
ECM

# UpToDate on PitNET. Adenomas research and management

RESPONSABILI SCIENTIFICI

**Prof.ssa Laura De Marinis**

**Dott. Antonio Bianchi**



UNIVERSITÀ  
CATTOLICA  
del Sacro Cuore

ROME

**28<sup>th</sup> 29<sup>th</sup>**  
November 2024

**Hotel Donna Camilla Savelli**  
Via Garibaldi 27 Roma

## 1st DAY | **Thursday, 28** November 2024

**14.00** Registration

**14.30**

*Introduction*

**L. De Marinis, A. Pontecorvi**

**G. Fioroni** - *Vicepresidente Fondazione Policlinico Universitario A. Gemelli*

*Welcome Speech*

**R. Cozzi, L. Festa, A. Gasbarrini, A. Isidori, A. Lenzi, C. Motta, A. Pontecorvi**

### **PRESIDENTIAL LECTURE**

*Chairmen: A. Lenzi, A. Pontecorvi*

**15.00** New consensus guidelines for medical therapy in acromegaly - **A. Giustina**

### **I SESSION: New knowledges and acquisitions on PitNETs**

*Chairmen: E. D. Capoluogno, E. De Menis, G. Rindi*

*Discussant: M. L. Jaffrain-Rea, G. L. Scaglione, M. Zollino*

**15.30** PitNET/adenoma WHO classification and GH hypersecretion - **M. Gessi**

**15.50** Difference in the diagnosis of T-PIT lineage in PitNETs- **F. Roncaroli**

**16.10** Therapeutic targeting of the PitNET/adenoma microenvironment - **G. Raverot**

**16.30** Predictors of biochemical response to SRLs in acromegaly - **M. Puig Domingo**

**16.50** Any role of medical treatment in not functioning PitNET/adenoma?  
**G. Mantovani**

**17.10** Targeting somatostatin and dopamine receptors: is there a role for chimeric molecules? – **F. Gatto**

**17.30** Radiotherapy for aggressive PitNETs - **G. Minniti**

**17.40** Discussion

### **PRESIDENTIAL LECTURE**

*Chairmen: D. Ferone, M. C. Zatelli*

**18.10** Gender differences in PitNET - **A. Colao**

**18.40** Conclusions

## 2nd DAY | **Friday, 29** November 2024

**08.30** Registration

### **09.00 PRESIDENTIALE LECTURE**

*Chairmen: E. Ghigo, P. Zuppi*

Deficit of Prolactin as a new medical entity - **F. Casanueva**

### **II SESSION: The emerging aspects of pituitary diseases**

*Chairmen: A. M. Isidori, P. Maffei*

*Discussant: R. Baldelli, A. Spada, G. Vitale*

**09.30** GHD and reproduction - **A. M. Isidori**

**09.50** The direct impact of octreotide and pegvisomant on osteoblast proliferation and function - **G. Mazziotti**

**10.10** Endocrine disruptors, aryl hydrocarbon receptor and cortisol secretion - **S. Cannavò**

**10.30** **Coffee Break**

**10.45** GH DEFICIT: new formulation of long acting GH in pediatric e adult age - **S. Grottoli**

**11.05** Bone fragility as a marker of hypopituitarism - **S. Frara**

**11.25** Discussion

### **11.45 PRESIDENTIAL LECTURE**

*Chairmen: G. Rindi, V. Rufini*

Peptide Receptor Radionuclide Therapy of Neuroendocrine Tumors: Agonist, Antagonist and Alternatives - **D. Ferone**

### **III SESSION: Multidisciplinary management of difficult aggressive ACTH pituitary tumors**

*Chairmen: A. G. Lania, C. Scaroni*

*Discussant: L. Lauretti, M. Rigante, C. Simeoli, T. Tartaglione*

**12.15** Epidemiology and mortality of Cushing's syndrome - **N. Karavitaki**

**12.35** Surgical strategies in Cushing disease- **F. Doglietto**

**12.55** Diagnostic challenges in cyclic Cushing syndrome - **M. Reincke**

**13.15** Role of medical treatments in Cushing disease - **R. Pivonello**

**13.35** **Light Lunch**

**14.20** Role of nuclear medicine in diagnosis of ACTH secreting PitNETs and NETs  
**C. Caldarella**

**14.40** Gene Involvement in Pituitary Corticotroph Tumors - **G. Trivellin**

**15.10** The histology of pituitary corticotrophin tumors - **L. Poliani**

**15.30** Role of radiology - **S. Gaudino**

**15.50** Role of Radiotherapy - **C. Mazzarella**

**16.00** Discussion

**16.30** Closing remarks  
CME Evaluation

## **FACULTY**

**Gianluca Aimaretti**, *Novara*

**Roberto Baldelli**, *Roma*

**Antonio Bianchi**, *Roma*

**Carmelo Caldarella**, *Roma*

**Salvatore Cannavò**, *Messina*

**Ettore Domenico Capoluogno**, *Roma*

**Felipe Casanueva**, *Santiago De Compostela*

**Sabrina Chiloiro**, *Roma*

**Annamaria Colao**, *Napoli*

**Renato Cesare Cozzi**, *Milano*

**Laura De Marinis**, *Roma*

**Ernesto De Menis**, *Treviso*

**Francesco Doglietto**, *Roma*

**Diego Ferone**, *Genova*

**Lucia Festa**, *Roma*

**Giuseppe Fioroni**, *Roma*

**Stefano Frara**, *Torino*

**Antonio Gasbarrini**, *Roma*

**Federico Gatto**, *Genova*

**Simona Gaudino**, *Roma*

**Marco Gessi**, *Roma*

**Ezio Ghigo**, *Torino*

**Antonella Giampietro**, *Roma*

**Andrea Giustina**, *Milano*

**Silvia Grottoli**, *Torino*

**Andrea Isidori**, *Roma*

**Marie Lise Jaffrain - Rea**, *L'Aquila*

**Niki Karavitaki**, *Birmingham*

**Andrea Gerardo Lania**, *Milano*

**Liverana Lauretti**, *Roma*

**Andrea Lenzi**, *Roma*

**Pietro Maffei**, *Padova*

**Giovanna Mantovani**, *Milano*

**Ciro Mazzarella**, *Roma*

**Gherardo Mazziotti**, *Milano*

**Domenico Milardi**, *Roma*

**Giuseppe Minniti**, *Roma*

**Cecilia Motta**, *Roma*

**Rosario Pivonello**, *Napoli*

**Luigi Poliani**, *Milano*

**Alfredo Pontecorvi**, *Roma*

**Manel Puig-Domingo**, *Barcellona*

**Gerald Raverot**, *Lione*

**Martin Reincke**, *Monaco*

**Mario Rigante**, *Roma*

**Guido Rindi**, *Roma*

**Federico Roncaroli**, *Manchester*

**Vittoria Rufini**, *Roma*

**Giovanni Luca Scaglione**, *Roma*

**Carla Scaroni**, *Padova*

**Chiara Simeoli**, *Napoli*

**Antonio Spada**, *Roma*

**Tommaso Tartaglione**, *Roma*

**Giampaolo Trivellin**, *Vidalengo*

**Giovanni Vitale**, *Milano*

**Maria Chiara Zatelli**, *Ferrara*

**Marcella Zollino**, *Roma*

**Paolo Zuppi**, *Roma*